Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth Subsalicylate for Clostridium Difficile Infection
NCT03592082Phase 4Withdrawn
- Sponsor
- Bassett Healthcare Network
- Start
- Mar 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bismuth subsalicylate in Clostridioides difficile infection (CDI) (2 arms), sponsored by Bassett Healthcare Network. Primary endpoint: Length of stay at 70 days. Planned start Mar 2018; status: withdrawn.
02
Drugs
bismuth subsalicylate
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03592082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03592082.